We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Pieris Pharmaceuticals and Roche Group subsidiary Genentech have signed a multi-programme research partnership and licence agreement worth approximately $1.42bn to discover, develop and market respiratory and ophthalmology therapies.